Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
基本信息
- 批准号:10687821
- 负责人:
- 金额:$ 67.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-20 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAccelerationAcute Respiratory Distress SyndromeAddressAlveolarAneurysmAnimal ModelAtherosclerosisAttenuatedBiological AvailabilityBlood PlateletsBody Weight decreasedCOVID-19COVID-19 preventionCOVID-19 severityCOVID-19 treatmentCell membraneCellsClinical TrialsCoagulation ProcessCommunicable DiseasesComplementComplement 3 ConvertaseComplement 5aComplement ActivationComplement Membrane Attack ComplexDepositionDevelopmentEndothelial CellsEndotheliumErythrocytesFosteringFunctional disorderHemolysisHumanImmunologyInfectionInflammationInvestigationK-18 conjugateKnock-inKnock-outLungMacrophageMannose Binding LectinMediatingModelingMonoclonal AntibodiesMusMyeloid Cell ActivationMyeloid CellsOrganPathogenesisPathologicPathway interactionsPlatelet ActivationPredispositionRationalizationResearchRiskRoleSARS-CoV-2 infectionSARS-CoV-2 pathogenesisSARS-CoV-2 variantSafetySiteSystemTestingTherapeuticThrombosisTransgenic MiceVascular DiseasesVascular Permeabilitiesactivation productcell injuryclinically relevantcomplement systemimmune activationinhibitorinterestinterstitialmembrane assemblymortalitynovel therapeutic interventionoverexpressionresponsesecondary infectionsevere COVID-19single-cell RNA sequencingtherapeutic evaluationtoolvascular inflammation
项目摘要
Project summary/Abstract: In response to Notice of Special Interest (NOSI): Complement in Basic
Immunology (CIBI), we propose to examine the causative effect of complements in the pathogenesis of severe
COVID-19. The complement system is activated via one of three pathways—classical, alternative, and
mannose-binding lectin (MBL)—which converge at C3 cleavage, leading to the formation of C3 and C5
convertases and concluding with assembly of the membrane attack complex (MAC). MAC is a cytolytic
macromolecular pore that can insert into host cell membranes under pathological conditions. Extensive
evidence obtained from others and us indicates that the complement (C) system, in particular MAC, may
participate in mediating endothelial damage, activating the coagulation pathway and platelets, and causing
multiple organ damage leading to severe COVID-19. However, the causative roles of C and MAC in severe
COVID-19 have not been experimentally investigated. The proposed studies will utilize our newly developed
state-of-the-art tools to block or modify the C activation products to investigate the role of C in endothelial cell
damage, platelet activation, and thrombosis formation seen in severe COVID-19, including therapeutic
paradigms. To address our needs, we have established and characterized an animal model of severe COVID-
19 using SARS-CoV-2-infected K18-hACE2 mice. The mice develop acute respiratory distress syndrome
(ARDS), progressive weight loss, and mortality at 7 days that is associated with severe interstitial inflammation,
perivascular inflammation, platelet activation, and thrombosis in the lungs. We also observe (i) endothelial cell
(EC) dysfunction of the alveolar septa; (ii) increased vascular permeability associated with the extensive
activation of immune cells (e.g., lung macrophage cells); and (iii) increased C3 and MAC deposition in
pulmonary vasculature. In addition, single-cell RNAseq shows C activation and coagulation in the lungs of this
severe COVID-19 model. These results have prompted us to hypothesize that the C in general, and MAC in
particular, significantly contribute to the EC damage, platelet activation, and thrombosis formation seen in
severe cases of COVID-19. Aim 1 will investigate whether the inhibition of C activation and MAC formation will
reduce EC damage and platelet and coagulation pathway activation in SARS-CoV-2-infected K18 mice. Aim 2
will test the hypothesis that the restriction of MAC formation will protect against EC damage and activation of
the myeloid cells, leading to reduced platelet and coagulation activation in SARS-CoV-2-infected K18 mice.
Aim 3 will investigate the role of C in the pathogenesis of SAR-CoV-2 infection in a clinically relevant paradigm and
evaluate site-targeted C inhibition as a treatment for COVID-19. help us better understand the role of C activation
and the MAC in pathogenesis of severe COVID-19, open a new avenue to prevent and treat COVID-19, and foster
the development of new therapeutic strategies involving modulation of the C system.
项目摘要/摘要:对特别利益通知的回应:基本补充
免疫学(Cibi),我们建议研究补体在重症肝炎发病机制中的致病作用。
新冠肺炎。补体系统通过三种途径之一激活--经典途径、替代途径和
甘露糖结合凝集素(MBL)--聚集在C3裂解处,导致C3和C5的形成
转化酶,并以膜攻击复合体(MAC)的组装结束。Mac是一种溶细胞剂
在病理条件下可以插入宿主细胞膜的大分子孔。广泛性
从其他人和我们那里获得的证据表明,补体(C)系统,特别是MAC,可以
参与介导内皮细胞损伤,激活凝血途径和血小板,并导致
多器官损害导致严重新冠肺炎。然而,C和MAC在重症中的致病作用
新冠肺炎还没有被实验性地调查过。拟议的研究将利用我们新开发的
最先进的工具来阻断或修饰C激活产物以研究C在内皮细胞中的作用
严重新冠肺炎的损害、血小板活化和血栓形成,包括治疗性
范例。为了满足我们的需求,我们建立了一种严重COVID的动物模型,并对其进行了表征-
19用SARS-CoV-2感染的K18-hACE2小鼠。小鼠出现急性呼吸窘迫综合征
(ARDS),进行性体重减轻,以及与严重间质炎症相关的7天死亡率,
肺部血管周围炎症、血小板活化和血栓形成。我们还观察到(I)内皮细胞
(EC)肺泡间隔功能障碍;(Ii)血管通透性增加与广泛的
激活免疫细胞(如肺巨噬细胞);以及(Iii)增加C3和MAC在
肺血管系统。此外,单细胞RNAseq显示C活化和凝血在肺
严重的新冠肺炎模式。这些结果促使我们假设C一般,而MAC在
特别是,对EC损伤、血小板激活和血栓形成有显著促进作用
严重的新冠肺炎病例。目标1将调查C激活和MAC形成的抑制是否会
减少SARS-CoV-2感染的K18小鼠内皮细胞损伤及血小板和凝血通路的激活。目标2
将检验这样一种假设,即限制MAC形成将保护EC免受EC损伤和激活
髓系细胞,导致感染SARS-CoV-2的K18小鼠的血小板和凝血活性降低。
目的3将在一个临床相关的范例中研究C在SARS-CoV-2感染发病机制中的作用
评估部位靶向C抑制作为新冠肺炎的治疗方法。帮助我们更好地理解C激活的作用
而MAC在重症新冠肺炎的发病机制中,开辟了防治新冠肺炎的新途径,促进了
涉及调节C系统的新治疗策略的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xuebin Qin其他文献
Xuebin Qin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xuebin Qin', 18)}}的其他基金
Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
- 批准号:
10765317 - 财政年份:2023
- 资助金额:
$ 67.43万 - 项目类别:
Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
- 批准号:
10512248 - 财政年份:2022
- 资助金额:
$ 67.43万 - 项目类别:
Generation and Characterization of a Novel Cell Subpopulation Ablation Model
新型细胞亚群消融模型的生成和表征
- 批准号:
9932578 - 财政年份:2019
- 资助金额:
$ 67.43万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8791256 - 财政年份:2013
- 资助金额:
$ 67.43万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8725332 - 财政年份:2013
- 资助金额:
$ 67.43万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8438708 - 财政年份:2013
- 资助金额:
$ 67.43万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
9001317 - 财政年份:2013
- 资助金额:
$ 67.43万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8607165 - 财政年份:2013
- 资助金额:
$ 67.43万 - 项目类别:
相似海外基金
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 67.43万 - 项目类别:
Continuing Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
- 批准号:
23H01186 - 财政年份:2023
- 资助金额:
$ 67.43万 - 项目类别:
Grant-in-Aid for Scientific Research (B)